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To the Editor, 
We read with great interest the recent publica-
tion by Arıkan et al. on central retinal artery occlu-
sion  (CRAO)  in  a  newly  diagnosed  patient  with 
essential thrombocythemia (ET), and their conclu-
sion that ET is among the underlying hematologic 
disorders in patients with CRAO [1]. ET is a myelo-
proliferative disorder associated with an increase in 
abnormal  platelets  that  causes  both  hemorrhagic 
and  thrombotic  pathology.  Some  of  its  systemic 
complications include deep vein thrombosis, pul-
monary emboli, myocardial infarcts, and renal ves-
sel  thrombosis  [2].  We  would  like  to  share  our 
experience  concerning  the  causative  relationship 
between ET and CRAO. 
A  29-year-old  male  presented  with  acute  visual 
loss in his right eye. Upon examination his right eye 
visual acuity (VA) was counting fingers at 0.5 m and 
the relative afferent pupillary defect was positive in 
the same eye. Fundus examination revealed retinal 
edema  and  a  cherry-red  spot  appearance  of  the 
macula with narrowed vessels, which were compat-
ible  with  the  diagnosis  of  CRAO.  Ocular  massage, 
anterior chamber paracentesis, and systemic therapy 
with  a  carbonic  anhydrase  inhibitor  and  mannitol 
were initiated. At presentation the patient’s routine 
laboratory test results were normal, except for throm-
bocytosis  (platelet  count:  1.278×109/L);  following 
this result, the patient was referred to our clinic. 
The patient had a history of diabetes mellitus type 
1  (controlled  with  insulin).  The  patient’s  platelet 
count  was  1.324×109/L,  which  was  in  accordance 
with  the  peripheral  blood  smear  that  showed  an 
increase in the number of platelets and clumps, and 
bone marrow biopsy showed an increase in the num-
ber of megakaryocytes. The white blood cell count 
was  11.6×109/L  and  hemoglobin  was  15.5  g/dL. 
Physical and ultrasonographic examination showed 
splenomegaly. Hematological results for prothrom-
bin  time,  partial  thromboplastin  time,  fibrinogen, 
antithrombin III, protein C, protein S, activated pro-
tein C resistance, lupus anticoagulant, antinuclear 
antibody,  and  the  erythrocyte  sedimentation  rate 
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17.9  (normal  range:  5.4-16.2  μmol/L).  Factor  V 
Leiden  1691  G>A  and  factor  II  20210  G>A  were 
normal. 
Conventional cytogenetic analysis of a bone mar-
row specimen was normal. The patient was hetero-
zygous for JAK2 V617F mutation, based on real time 
PCR  analysis.  The  final  diagnosis  of  ET  was  then 
established. Therapeutic thrombopheresis was per-
formed once, followed by low-dose acetyl salicylic 
acid  and  hydroxyurea  treatment.  At  the  1-month 
follow-up the patient’s platelet count was within the 
normal range, but his VA had not improved com-
pletely. Maintenance therapy was planned for the 
appropriate dose and duration. 
ET is associated with systemic and ocular throm-
botic  and  embolic  complications.  The  risk  for 
thrombosis is highest in patients with a history of 
thrombosis  and  in  those  aged  >60  years  [3]. 
Although ET is primarily considered a disorder of 
middle-advanced age, it has been observed in chil-
dren and young adults; however, the actual risk for 
thrombosis in young patients has not been clearly 
established  [4].  We  think  that  this  complication 
should be kept in mind, especially in young adult 
patients with acute visual loss.
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